RNA for injection (IRNA for lung cancer)

A. RNA for injection (IRNA against malign tumors)

These products are white or near white freeze dried aseptic preparations extracted and refined using modern biotechnology. They are extracted from the liver, spleen and lymph nodes on sheep with acquired immunity after special treatment with tumor tissues:
1. IRNA against gastric cancer authorization: ZWYZZ (1996) No. 202301;
2. IRNA against esophagus carcinoma authorization: ZWYZZ (1996) No. 228001;
3. IRNA against rhinopharyngeal carcinoma authorization: ZWYZZ (1996) No. 229801;
4. IRNA against breast cancer authorization: ZWYZZ (1996) No. 225401;
5. IRNA against lung cancer authorization: ZWYZZ (1996) No. 225301;
6. IRNA against liver cancer authorization: ZWYZZ (1996) No. 225601;
7. IRNA against adenocarcinoma authorization: ZWYZZ (1996) No. 225501;

These products have no drug-resistance and no adverse side effects. They can enhance the immune system by stimulating the immunological cells in the body to destroy the cancer cells, resulting in specific immunity against cancer. Best used in conjunction with radiotherapy or chemotherapy, or after operation.
[Usage] specification: 2mg per vial; dissolve in 2ml of water for injection before use; intramuscular or hypodermic injection; 1-4mg each time; twice per week or as directed by the doctor; course of treatment lasts 3 months.
[Storage] cool, dry storage in tightly sealed vessel.
The products are widely praised after nearly 30,000 clinical cases in large hospitals in the nation. According to the statistics from 305 cases in 5 hospitals, including the 3rd hospital of Bethune Medical University, the overall effective rate of the products is 90%, and the rate to 3rd stage cancer is 78.9%.